Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 6, 2004. The report serves as a disclosure of changes in directors' interests in the company's Ordinary Shares and American Depository Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on director share allocations and does not contain consolidated financial statements or performance metrics.
Material Changes
The primary material change disclosed is the provisional allocation of share awards to Non-Executive Directors on December 31, 2003. These awards resulted from the annual reinvestment of dividends paid throughout 2003. The allocations cover both former SmithKline Beecham directors and current GlaxoSmithKline directors.
Management Commentary and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory disclosure of equity ownership changes.
Important Facts for Investors
- Share Allocations: Non-Executive Directors received Ordinary Shares and ADSs via dividend reinvestment plans effective December 31, 2003.
- Valuation Data: The average price for Ordinary Shares was £12.76, while the average price for ADSs was $46.183.
- Notification Date: The company was notified of these changes on January 5, 2003 (as stated in the text, though the filing date is January 6, 2004).
- Scope Limitation: This filing does not contain financial performance data for the period.